

GILEAD SCIENCES INC  
Form 8-K  
July 31, 2003

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):**

**July 31, 2003**

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other jurisdiction of  
incorporation or organization)

**0-19731**

(Commission File Number)

**94-3047598**

(I.R.S. Employer  
Identification No.)

**333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA**

(Address of principal executive offices)

**94404**

(Zip Code)

**(650) 574-3000**

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

(Registrant's telephone number, including area code)

---

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits

Exhibit Number	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on July 31, 2003

**ITEM 9. REGULATION FD DISCLOSURE (ALSO BEING FILED UNDER NEW ITEM 12. DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION).**

On July 31, 2003, Gilead Sciences, Inc., a Delaware corporation, issued a press release announcing earnings for the quarter and six months ended June 30, 2003. A copy of the earnings press release is filed as Exhibit 99.1 to this report.

Each non-GAAP financial measure presented in the earnings press release is included because our management uses this information to monitor and evaluate on-going operating results and trends excluding certain items. Our management believes the non-GAAP information is also useful for investors because the in-process research and development charge relating to the acquisition of Triangle Pharmaceuticals, Inc. in January 2003 was the result of a transaction that is unusual due to its nature, size and infrequency. Consequently, excluding this charge from our operating results provides users of the financial statements an important insight into our operating results and related trends that affect our core business.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	<b>GILEAD SCIENCES, INC.</b>
	(registrant)
	/s/John F. Milligan
	John F. Milligan Senior Vice President and Chief Financial Officer
Date: July 31, 2003	

Exhibit Index

Exhibit Number	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on July 31, 2003